Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure

NCT01970501 is registered in ClinicalTrials.gov with ARCA Biopharma, Inc. as lead sponsor.

NCT NCT01970501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01970501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure
Lead sponsor
ARCA Biopharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2014
Completion date
December 28, 2017
Enrollment
267 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

current or recent history of atrial fibrillation